Apolipoprotein E receptor 2 (ApoER2)

Apolipoprotein E receptor 2 (ApoER2), also known as LRP8, is a type-I transmembrane receptor belonging to the low-density lipoprotein (LDL) receptor family (NIH, 2012; Wikipedia, 2024). It is predominantly expressed in the central nervous system, where it serves as a critical component of the Reelin signaling pathway, governing neuronal migration during development and maintaining synaptic plasticity and memory function in the adult brain (NIH, 2012; MDPI, 2023). ApoER2 is heavily implicated in the pathogenesis of Alzheimer's disease through its interactions with Apolipoprotein E (ApoE) and the amyloid precursor protein (APP), which modulate the production and clearance of amyloid-beta (Aβ) plaques (NIH, 2012; ResearchGate, 2021). Additionally, the receptor plays a significant role in the vasculature and immune system, particularly as a mediator of prothrombotic signaling in Antiphospholipid Syndrome (APS) upon binding to beta-2-glycoprotein I (NIH, 2011; Frontiers in Immunology, 2023). Although direct pharmacological modulators of ApoER2 are currently in the experimental stage, the receptor remains a high-priority therapeutic target for neurodegenerative disorders and autoimmune-mediated thrombosis (NIH, 2020; Open Targets, 2024).

Other names

LRP8Low-density lipoprotein receptor-related protein 8Reelin receptorMCI1HSZ75190

Modulation of lipid metabolism and cholesterol homeostasis; activation of Reelin-mediated signal transduction; inhibition of amyloid-beta production; blocking of pathogenic autoantibody binding in antiphospholipid syndrome.